Drugs / delolimogene mupadenorepvec
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04123470 | Jan 2020 → Jul 2023 | melanoma | Lokon Pharma AB | Completed | No outcome recorded |
| Phase 1/2 | NCT02705196 | Nov 2016 → Nov 2025 | malignant pancreatic neoplasm | Lokon Pharma AB | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-02-17 | Lokon Pharma AB | Results Results from first melanoma trial using LOAd703 tumor microenvironment gene engineering in combination with immune checkpoint inhibition is published in Nature Communications mynewsdesk.com ↗
we have demonstrated the safety in ICI refractory patients with antitumor activity.1 |
| 2025-01-10 | Lokon Pharma AB | Regulatory Lokon Pharma receives FDA Fast Track Designation for LOAd703 for the treatment of Pancreatic Cancer mynewsdesk.com ↗
the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company´s product candidate LOAd703 for the treatment of pancreatic cancer. |
| 2024-03-26 | Lokon Pharma AB | Results Results from first pancreatic cancer trial using immunostimulatory gene therapy is published in Lancet Oncology mynewsdesk.com ↗
Results from Arm 1 have now been published Lancet Oncology. |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | delolimogene mupadenorepvec | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02705196 ↗ |
| Route | Other | “In this study, LOAd703 will be given by intratumoral injections.” NCT02705196 ↗ |